Form 4: Saba Capital Management Reduces Stake in BlackRock Capital Allocation Term Trust

Saba Capital Management, a 10% owner of BlackRock Capital Allocation Term Trust, has reported selling shares of common stock over two days.

Summary

• Saba Capital Management, L.P., a significant shareholder in BlackRock Capital Allocation Term Trust (BCAT), has disclosed transactions involving the sale of BCAT common stock.
• On February 18, 2025, Saba Capital sold 47,152 shares at a price of $15.57 per share.
• Following this transaction, Saba Capital's indirect beneficial ownership amounted to 12,737,795 shares.
• On February 19, 2025, the firm sold an additional 28,628 shares at $15.53 per share, resulting in a beneficial ownership of 12,709,167 shares.
• The transactions were reported by Saba Capital Management, L.P., with Zachary Gindes signing on behalf of the firm, and by Boaz Weinstein.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the reduction in Saba Capital's stake, which could indicate a lack of confidence or a shift in investment strategy. However, the magnitude of the sale is relatively small compared to their overall holdings.

Negatives

• Saba Capital Management reduced its stake in BlackRock Capital Allocation Term Trust.

Risks

• Continued selling pressure from Saba Capital could negatively impact BCAT's stock price.

Industry Context

Hedge funds like Saba Capital often adjust their positions in closed-end funds like BCAT to manage portfolio risk and capital allocation.

Stakeholder Impact

• Shareholders may react to the news of Saba Capital reducing its stake.
• The market could interpret the sale as a signal, potentially affecting the stock price.

Key Dates

Keywords

Saba Capital Management, BlackRock Capital Allocation Term Trust, BCAT, share sale, beneficial ownership, Form 4, Boaz Weinstein, Zachary Gindes